User profiles for Susana Banerjee
 | susana banerjeeThe Royal Marsden NHS Foundation Trust Verified email at doctors.org.uk Cited by 18826 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, K Fujiwara, I Ray-Coquard, S Banerjee… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
…, J Ledermann, S Williams, S Banerjee… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …
Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient …
…, A Gravina, C Abdeddaim, S Banerjee… - JAMA …, 2020 - jamanetwork.com
Importance Deficient mismatch mutation repair mechanisms may sensitize endometrial
cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an …
cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an …
[HTML][HTML] Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
…, GS Sonke, C Gourley, S Banerjee… - … England Journal of …, 2018 - Mass Medical Soc
Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised …
S Banerjee, KN Moore, N Colombo, G Scambia… - The Lancet …, 2021 - thelancet.com
Background There is a high unmet need for treatment regimens that increase the chance of
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …
long-term remission and possibly cure for women with newly diagnosed advanced ovarian …
Exploiting the folate receptor α in oncology
Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as methotrexate …
successful development of drugs targeting intracellular folate metabolism, such as methotrexate …
[HTML][HTML] Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
…, L Welsh, N van As, RL Jones, J Droney, S Banerjee… - Nature cancer, 2021 - nature.com
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200) …
…, C Sessa, K Yonemori, S Banerjee… - The lancet …, 2021 - thelancet.com
Background Most patients with ovarian cancer will relapse after receiving frontline platinum-based
chemotherapy and eventually develop platinum-resistant or platinum-refractory …
chemotherapy and eventually develop platinum-resistant or platinum-refractory …
Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG …
P DiSilvestro, S Banerjee, N Colombo… - Obstetrical & …, 2023 - journals.lww.com
Because of nonspecific symptoms at disease presentation and inadequate screening methods,
ovarian cancer is often advanced at the time of diagnosis results in a 10-year survival of …
ovarian cancer is often advanced at the time of diagnosis results in a 10-year survival of …
New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential
S Banerjee, SB Kaye - Clinical cancer research, 2013 - AACR
The treatment of ovarian cancer is set to undergo rapid changes, as strategies incorporating
molecular targeted therapies begin to take shape. These are based on a better appreciation …
molecular targeted therapies begin to take shape. These are based on a better appreciation …